485 related articles for article (PubMed ID: 17093476)
1. Patenting race.
Kahn J
Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
[TBL] [Abstract][Full Text] [Related]
2. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
3. Patent fight sparks biological warfare in the drug industry.
Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
[No Abstract] [Full Text] [Related]
4. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
5. Patent crunch pending.
Wadman M
Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
[No Abstract] [Full Text] [Related]
6. Bilski blundering biotech.
Simmons WJ
Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
[No Abstract] [Full Text] [Related]
7. Pharmaceutical patent life-cycle management after KSR v. Teleflex.
Furrow ME
Food Drug Law J; 2008; 63(1):275-320. PubMed ID: 18561462
[No Abstract] [Full Text] [Related]
8. Putting your best mode forward.
Tsao YR; Tabtiang RK
Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
[No Abstract] [Full Text] [Related]
9. Negotiating the RNAi patent thicket.
Schmidt C
Nat Biotechnol; 2007 Mar; 25(3):273-5. PubMed ID: 17344871
[No Abstract] [Full Text] [Related]
10. "Ganske" threatens biotechnology patents worldwide.
Glaser V
Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
[No Abstract] [Full Text] [Related]
11. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
12. Robert Stoll. Interview by Charlotte Harrison.
Stoll R
Nat Rev Drug Discov; 2009 Dec; 8(12):926. PubMed ID: 19949397
[No Abstract] [Full Text] [Related]
13. Patenting of genetic material: are the benefits to society being realized?
Willison DJ; MacLeod SM
CMAJ; 2002 Aug; 167(3):259-62. PubMed ID: 12186174
[No Abstract] [Full Text] [Related]
14. Hatch-waxman changes debated.
Chahine K
Nat Biotechnol; 2000 Jul; 18(7):710-1. PubMed ID: 10888831
[No Abstract] [Full Text] [Related]
15. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
16. The 1992 biotechnology agenda: a message for candidates Bush and Clinton.
Duzan SA
Healthspan; 1992 Sep; 9(8):12-5. PubMed ID: 10122052
[No Abstract] [Full Text] [Related]
17. Cabilly patent finale.
Waltz E
Nat Biotechnol; 2008 Aug; 26(8):846. PubMed ID: 18688222
[No Abstract] [Full Text] [Related]
18. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
Teitelbaum R; Cohen M
Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
[No Abstract] [Full Text] [Related]
19. Patent prosecution of biotechnology and pharmaceutical patents in a changing legal landscape.
Lu DL; Kowalski TJ; Jarecki-Black J
Future Med Chem; 2010 Jan; 2(1):7-9. PubMed ID: 21426040
[No Abstract] [Full Text] [Related]
20. [Federal judge and government of the United States against gene patenting].
Cassier M; Stoppa-Lyonnet D
Med Sci (Paris); 2011; 27(6-7):662-6. PubMed ID: 21718652
[No Abstract] [Full Text] [Related]
[Next] [New Search]
